Related Experiment Video
Updated: Apr 28, 2026
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors
Satoshi Sogabe1, Youichi Kawakita1, Shigeru Igaki1
1Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Abstract:
The epidermal growth factor receptor (EGFR) family plays a critical role in vital cellular processes and in various cancers. Known EGFR inhibitors exhibit distinct antitumor responses against the various EGFR mutants associated with nonsmall-cell lung cancer. The L858R mutation enhances clinical sensitivity to gefitinib and erlotinib as compared with wild type and reduces the relative sensitivity to lapatinib. In contrast, the T790M mutation confers drug resistance to gefitinib and erlotinib. We determined crystal structures of the wild-type and T790M/L858R double mutant EGFR kinases with reversible and irreversible pyrrolo[3,2-d]pyrimidine inhibitors based on analogues of TAK-285 and neratinib. In these structures, M790 adopts distinct conformations to accommodate different inhibitors, whereas R858 allows conformational variations of the activation loop. These results provide structural insights for understanding the structure-activity relationships that should contribute to the development of potent inhibitors against drug-sensitive or -resistant EGFR mutations.
Insights
Understanding epidermal growth factor receptor (EGFR) mutations in lung cancer is key. New crystal structures reveal how EGFR mutations like L858R and T790M affect drug sensitivity, guiding the development of targeted therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Epidermal growth factor receptor (EGFR) signaling is crucial for cellular functions and implicated in cancer development.
- Specific EGFR mutations, such as L858R and T790M, influence the efficacy of targeted therapies in non-small cell lung cancer (NSCLC).
Purpose of the Study:
- To elucidate the structural basis of differential drug responses in EGFR mutants.
- To provide insights for designing novel EGFR inhibitors targeting both sensitive and resistant mutations.
Main Methods:
- Determined crystal structures of wild-type and T790M/L858R mutant EGFR kinases.
- Utilized reversible and irreversible pyrrolo[3,2-d]pyrimidine inhibitors, analogues of TAK-285 and neratinib.
Main Results:
- Observed distinct conformations of M790 in response to different inhibitors.
- Demonstrated that R858 facilitates conformational changes in the EGFR activation loop.
- Characterized the structural basis for varying sensitivity to EGFR inhibitors based on specific mutations.
Conclusions:
- Structural insights into EGFR mutations and inhibitor interactions are vital for understanding structure-activity relationships.
- These findings will aid in the rational design of more effective EGFR inhibitors for NSCLC treatment.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase